Design Therapeutics (DSGN) Interest Income - Total (2024 - 2026)
Design Therapeutics (DSGN) posted quarterly Interest Income - Total of $2.0 million for Q2 2026, down 19.07% year-over-year from $2.5 million in Q2 2025, and down 2.8% on a QoQ basis from $2.1 million in Q1 2026.
Design Therapeutics (DSGN) Interest Income - Total (2024 - 2026) Analysis & Trends
Design Therapeutics has reported Interest Income - Total for 3 years, with the latest figure at $2.0 million in Q2 2026.
- Interest Income - Total for Q2 2026 came in at $2.0 million, down 19.07% year-over-year; the trailing twelve-month figure through Jun 2026 was $8.6 million (down 25.1% YoY), and the FY2025 annual result was $9.7 million, down 24.38% from the prior year.
- Interest Income - Total declined to $2.0 million in Q2 2026, from $2.1 million in the prior quarter.
- Over five years, Interest Income - Total peaked at $3.3 million in Q1 2024 and troughed at $2.0 million in Q2 2026.
- A 3-year average of $2.7 million and a median of $2.6 million in 2025 frame the typical range for Interest Income - Total.
- The largest YoY upside for Interest Income - Total was 17.97% in 2025 against a maximum downside of 28.62% in 2025.
- A 3-year view of Interest Income - Total shows it stood at $3.0 million in 2024, then decreased by 28.62% to $2.2 million in 2025, then decreased by 7.37% to $2.0 million in 2026.
- Per Business Quant data, the three most recent Interest Income - Total figures were $2.0 million in Q2 2026, $2.1 million in Q1 2026, and $2.2 million in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Interest Income - Total (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | - |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | - |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | - |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | - |
| 10 | Design Therapeutics | 928.06 Mn | 720.67 Mn | - | 2.01 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 2.01 Mn |
| Jun 30, 2026 | 2.01 Mn |
| Mar 31, 2026 | 2.07 Mn |
| Mar 31, 2026 | 2.07 Mn |
| Dec 31, 2025 | 2.17 Mn |
| Dec 31, 2025 | 2.17 Mn |
| Sep 30, 2025 | 2.31 Mn |
| Sep 30, 2025 | 2.31 Mn |
| Jun 30, 2025 | 2.49 Mn |
| Jun 30, 2025 | 2.49 Mn |
| Mar 31, 2025 | 2.70 Mn |
| Mar 31, 2025 | 2.70 Mn |
| Dec 31, 2024 | 3.04 Mn |
| Dec 31, 2024 | 3.04 Mn |
| Sep 30, 2024 | 3.21 Mn |
| Sep 30, 2024 | 3.21 Mn |
| Jun 30, 2024 | 3.25 Mn |
| Jun 30, 2024 | 3.25 Mn |
| Mar 31, 2024 | 3.30 Mn |
| Mar 31, 2024 | 3.30 Mn |